Sleep and Circadian Dysfunction as Driver of Neurodegeneration

🧫 Experiment Protocol ClinicalNeurodegenerationCACNA1G/CLOCK/GABRA1humanproposed

# Sleep and Circadian Dysfunction as Driver of Neurodegeneration ## Background and Rationale This clinical study investigates whether sleep and circadian rhythm disruption actively drives neurodegeneration rather than being merely a symptom. The study employs a longitudinal design with cognitively normal adults at genetic risk for AD (APOE4 carriers). **Protocol**: 500 participants (ages 50-65, APOE4+, cognitively normal) undergo: (1) 2-week actigraphy + sleep diary at baseline, 12mo, 24mo, 36mo. (2) Polysomnography with slow-wave sleep (SWS) quantification at each timepoint. (3) Melatonin onset sampling (DLMO) to assess circadian phase. (4) CSF sampling at baseline and 36mo for amyloid-beta42, phospho-tau181, neurofilament light chain. (5) Amyloid PET at baseline and 36mo. **Primary Outcome**: Correlation between SWS reduction rate and amyloid PET SUVr change over 3 years. **Secondary**: Circadian phase shift magnitude vs. CSF biomarker trajectories. **Success Criteria**: If SWS decline >20% predicts amyloid accumulation with OR>2.0 (p<0.01) after controlling for age, sex, and APOE genotype, the causal hypothesis is supported. **Expected Timeline**: 4 years (1yr enrollment + 3yr follow-up). **Estimated Cost**: $8.5M. This experiment directly tests predictions arising from the following hypotheses: - **Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation** - **Circadian Glymphatic Rescue Therapy (Melatonin-focused)** - **Circadian-Synchronized Proteostasis Enhancement** - **Sleep Spindle-Synaptic Plasticity Enhancement** - **Biorhythmic Interference via Controlled Sleep Oscillations** ## Experimental Protocol **Phase 1: Participant Recruitment and Baseline Assessment (Weeks 1-4)** • Recruit 300 cognitively healthy adults aged 50-75 years through community outreach and medical centers • Screen participants using Mini-Mental State Examination (MMSE ≥26) and exclude those with existing neurological conditions • Obtain comprehensive medical history, medication review, and informed consent • Conduct baseline cognitive assessment using Montreal Cognitive Assessment (MoCA) and neuropsychological battery • Collect baseline blood samples for biomarker analysis (Aβ40, Aβ42, p-tau181, NfL) • Perform baseline brain MRI with structural and DTI sequences **Phase 2: Sleep and Circadian Monitoring (Weeks 5-8)** • Deploy 14-day actigraphy monitoring using wrist-worn ActiGraph GT9X devices • Conduct overnight polysomnography (PSG) at sleep laboratory for 2 consecutive nights • Measure circadian markers: salivary melatonin profiles (6 samples over 24h), core body temperature • Administer Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale • Assess circadian chronotype using Munich Chronotype Questionnaire • Monitor sleep architecture parameters: REM sleep %, slow-wave sleep %, sleep efficiency **Phase 3: Longitudinal Follow-up (Months 3-36)** • Conduct quarterly cognitive assessments using comprehensive neuropsychological battery • Repeat brain MRI at 12, 24, and 36 months to measure hippocampal volume and cortical thickness • Collect blood biomarkers every 6 months for longitudinal tracking • Perform annual lumbar puncture in consenting participants (n=150) for CSF biomarkers • Continuous sleep monitoring using home-based devices every 6 months • Track incident mild cognitive impairment (MCI) and dementia diagnoses **Phase 4: Data Analysis and Correlation (Months 37-42)** • Analyze sleep-wake cycle parameters using cosinor analysis and non-parametric circadian rhythm analysis • Correlate sleep dysfunction metrics with rate of cognitive decline using mixed-effects models • Examine associations between circadian disruption and neuroimaging changes • Assess sleep quality as predictor of biomarker progression using survival analysis • Control for confounders: age, sex, education, APOE4 status, comorbidities ## Expected Outcomes 1. **Sleep Architecture Deterioration**: Participants with <15% slow-wave sleep and >30% sleep fragmentation will show 2-fold increased rate of cognitive decline compared to good sleepers (effect size d=0.6) 2. **Circadian Rhythm Disruption**: Individuals with circadian amplitude <0.3 and phase delays >2 hours will demonstrate 40% greater hippocampal atrophy rate (2.5% vs 1.8% annual volume loss) 3. **Biomarker Progression**: Poor sleepers (PSQI >10) will exhibit 50% faster increase in plasma p-tau181 levels and 30% greater Aβ42/40 ratio decline over 36 months 4. **MCI Conversion Risk**: Sleep efficiency <75% and REM sleep <15% will predict 3-fold higher risk of MCI conversion (HR=3.2, 95% CI: 1.8-5.7) 5. **Dose-Response Relationship**: Each 10% decrease in sleep efficiency will correlate with 0.2 point annual decline in MoCA scores and 1.5% additional hippocampal volume loss 6. **CSF Biomarker Changes**: Severely disrupted sleepers will show 25% higher CSF tau/Aβ42 ratios and 40% elevated neurofilament light levels compared to normal sleepers ## Success Criteria • **Primary Endpoint Achievement**: Significant association between sleep dysfunction composite score and cognitive decline rate with p<0.001 and effect size Cohen's d≥0.5 • **Biomarker Validation**: At least 3 of 4 neurodegeneration biomarkers show significant correlation with sleep parameters (p<0.01) with AUC≥0.70 for prediction models • **Longitudinal Consistency**: Sleep-cognition associations remain significant after controlling for age, education, APOE4 status with adjusted R²≥0.25 • **Sample Size Adequacy**: Achieve 80% retention rate (≥240 participants) through 36-month follow-up with complete sleep and cognitive data • **Neuroimaging Correlation**: Sleep dysfunction predicts ≥15% additional variance in hippocampal atrophy beyond age-related decline (p<0.005) • **Clinical Relevance**: Sleep-based risk stratification model achieves ≥75% sensitivity and ≥70% specificity for predicting MCI conversion within 3 years

Source: wiki

🧫 Experiment Extras

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found